文献速递肝病

胰高血糖素样肽-1受体激动剂与有害饮酒患者肝脏相关结局及全因死亡率的关联:一项目标试验模拟研究

Association of Glucagon-Like Peptide-1 Receptor Agonists With Liver-Related Outcomes and All-Cause Mortality in Patients With Harmful Alcohol Use: A Target Trial Emulation Study.
PubMed 文献 · Am J Gastroenterol · 2025-06-10

该研究利用美国退伍军人电子健康记录模拟目标试验,将8040例酒精使用障碍筛查阳性且新启用GLP-1 RA者与8040例未启用者进行倾向性评分1:1匹配。GLP-1 RA使用与复合肝脏结局风险降低(aHR 0.70,95%CI 0.56-0.87)及死亡风险降低(aHR 0.43,95%CI 0.37-0.49)相关,且随访期间AUDIT-C阳性比值更低(aOR 0.75,95%CI 0.68-0.82)。

要点

  • GLP-1 RA使用与复合肝脏结局风险降低相关(aHR 0.70,95%CI 0.56-0.87)。
  • GLP-1 RA使用与全因死亡风险降低相关(aHR 0.43,95%CI 0.37-0.49)。
  • 司美格鲁肽周剂量每增加1 mg,复合肝脏结局aHR 0.50(95%CI 0.29-0.88),死亡aHR 0.33(95%CI 0.19-0.58)。

核心结论

  • 在这项观察性目标试验模拟研究中,GLP-1 RA使用与肝脏结局、死亡及有害饮酒风险降低相关。

研究设计与样本

  • 利用美国退伍军人电子健康记录模拟目标试验,比较2017年1月3日至2024年9月30日新启用GLP-1 RA者与对照,随访至结局或研究结束。
  • 将AUDIT-C筛查阳性的GLP-1 RA新使用者按倾向性评分1:1匹配未使用GLP-1 RA的患者,共匹配8040例GLP-1 RA启用者与8040例未启用者。

主要发现

  • GLP-1 RA使用与复合肝脏相关结局风险降低相关(aHR 0.70,95%CI 0.56-0.87)。
  • GLP-1 RA使用与死亡风险降低相关(aHR 0.43,95%CI 0.37-0.49)。
  • 司美格鲁肽使用者中,每周剂量每增加1 mg与复合肝脏相关结局风险降低相关(aHR 0.50,95%CI 0.29-0.88),与死亡风险降低相关(aHR 0.33,95%CI 0.19-0.58)。
  • GLP-1 RA使用与随访期间AUDIT-C阳性比值降低相关(aOR 0.75,95%CI 0.68-0.82)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Anecdotal observations report a decrease in craving for alcohol among patients taking glucagon-like peptide-1 receptor agonists (GLP-1 RA). We aimed to assess liver-related outcomes and mortality among individuals with harmful alcohol use who received GLP-1 RAs. METHODS: We emulated a target trial using the electronic health records of US Veterans with positive alcohol use disorders-concise score (AUDIT-C), comparing new initiators of GLP-1 RA between 1/3/2017 and 9/30/2024, with controls, with follow-up until outcomes or study end. Each GLP-1 RA new user with a positive AUDIT-C screen was propensity score (PS) matched 1:1 with a patient not on a GLP-1 RA. The primary outcomes were the time to a composite outcome of decompensation, hepatocellular carcinoma, liver-related death, and all-cause mortality. The secondary outcome was the proportion of patients with positive AUDIT-C scores. RESULTS: We matched 8,040 patients with positive AUDIT-C initiated on GLP-1 RA with 8,040 noninitiators. GLP-1 RA use was associated with a lower risk of composite liver-related outcomes (adjusted hazard ratio [aHR], 0.70; 95% confidence interval [CI] 0.56-0.87) and death (aHR 0.43, 95% CI 0.37-0.49). Among semaglutide users, a 1 mg/wk dose increase was associated with a reduced risk of composite liver-related outcomes (aHR 0.50, 95% CI 0.29-0.88) and death (aHR 0.33, 95% CI 0.19-0.58). GLP-1 RA use was also associated with lower odds of positive AUDIT-C during follow-up (adjusted Odds ratio 0.75, 95% CI 0.68-0.82). DISCUSSION: In this observational target trial emulation study, GLP-1 RA use was associated with a lower risk of liver outcomes, death, and harmful alcohol use.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. John BV, Bastaich D, Marchetti D, et al. Association of Glucagon-Like Peptide-1 Receptor Agonists With Liver-Related Outcomes and All-Cause Mortality in Patients With Harmful Alcohol Use: A Target Trial Emulation Study. Am J Gastroenterol. 2025. PMID: 40488647. doi:10.14309/ajg.0000000000003585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。